姓名：吴健 博士
职称：教授
E-MAIL: jian.wu@fudan.edu.cn
WWW: http://medicine.fudan.edu.cn/

研究方向
（1）肠道微生态改变与慢性炎症、代谢异常及肿瘤发生
（2）干细胞生物学与肝脏再生医学工程
（3）生物医学工程技术的临床转化
重要学术贡献
吴健博士曾获“美国肝脏研究基金会”授予的“肝脏****”称号。现为美国肝脏研究会会士（FAASLD）。曾多次获得中国、瑞典、美国国家级奖项，如：瑞典医学研究会****奖、美国国家研究服务奖、新颖探索课题研究奖、美国癌症基金会“新颖科研奖”等。先后在权威专业刊物发表研究论著、应邀评述、专题论述等达115余篇。引用超过4200次。参与编写英文专著10部，主编英文专著三部。担任五份国际专业期刊副主编、编委、二十余核心期刊编审。参与中国、美国、法国、英国、荷兰、香港等国家及地区科研项目评审，是教育部、科技进步奖评审者，受自然科学基金和科技部重点项目资助，是位长期从事教学、科研及管理学术带头人。
荣誉与获奖
1.1997 瑞典医学研究学会研究****奖
2.1997 美国国立卫生研究院国家服务研究奖，1997
3.2000 美国肝脏研究协会和肝脏基金会“肝脏****”奖
4.2000 加州大学戴维斯分校健康体系研究奖，2000
5.2001 中科院海外杰出****短期研究奖
6.2004 美国癌症协会研究奖
7.2004 美国国立卫生研究院探索研究奖
8.2006 加州大学戴维斯分校学术联合会新颖开发研究奖
9.2007 加州大学戴维斯医学中心生物技术转换奖
10.2012 南京市创新型科技人才奖
11.2013 全国纳米生物与医药技术专业委员会科技成果二等奖
12.2016 科技部专家库成员
13.2017 美国肝病研究会（AASLD）会士 （FAASLD）

国内外学术团体任职
1999-今： 生命科学前沿科学家永久会员
2001-今: 美国肝病研究会 (AASLD) 会员
2001-今: 美国基因及细胞治疗协会 (ASGCT) 会员.
2005-今: 国际干细胞研究会 (ISSCR) 会员
2010-今: 美国科学促进会 (AAAS) 会员
2007-今： 美国癌症研究会（AACR）会员
2015-今： 中国微生物协会成员
2017-今： 中国实验动物协会生物安全委员会委员
2017-今： 美国肝病研究会 (AASLD) 会士 （FAASLD）
2017-今： 上海医学会会员
科学期刊编委、编辑
2001-今 《Frontiers in Bioscience》主管编辑
2004-今 《Would Journal of Gastroenterology》编委及版面编辑
2009-今 《Gastroenterology & Hepatology Research》编委。
2014-今 《Austin Journal of Gastroenterology》副主编
2016-今 《Laboratory Investigation》 编委
2009-今 《临床胆病杂志》常务编委。
2016-今 《Stem Cells》 编委
2017-今《Hepatology Communication》编委
学术刊物审稿
2002-今：Journal of Pharmacology and Experimental Therapeutics, Molecular Therapy, Biochemical Pharmacology, Biochimica et Biophysica Acta, Journal of Control Release等期刊.
2003 -今：Gene Therapy, Molecular Therapy, Biochemical Pharmacology, Journal of Hepatology, Hepatology等期刊.
2005-今 ：Biotechnology and Applied Biochemistry, International Journal of Pharmaceutics, Journal of Biology Chemistry, American Journal of Physiology, Laboratory Investigation, Liver International, Digestive Disease Science, Molecular Medicine, Life Science, Transplantation, Plos One, America Journal of Transplantation, Liver transplantation, Cancer Letters, AntiCancer Research等期刊。
2009-今 《Antioxidants & Redox Signaling》。
2009-今 ：Oncogenesis, Oncogene, Stem Cells，European Journal of Gastroenterology & Hepatology, Current Cancer Drug Targets, Plos One, American Journal of Transplantation, Annals of Biomedical Engineering, Oncogenes等期刊。
校内学术机构任职
（1）基础医学院伦理委员会副主任委员
（2）基础医学院安全管理委员会委员
（3）病原生物系国际合作委员会主任
受邀学术报告
2017: Cell origins for hepatocellular carcinoma in non-alcoholic steatohepatitis progression and fibrosis. 复旦大学上海医学院-瑞典Karolinska 大学 联合学术研讨会 复旦大学上海医学院
2017: Dicosylhexaenoic Acid Reversed Progression of NASH to Hepatic Fibrosis in Mice by Increasing Ratio ω-3 over ω-6 Fatty Acids 68届美国肝病研究会(AASLD) 年会 美国华盛顿特区
2017: Hepalatide Ameliorated Progression of nonalcoholic steatohepatitis in mice caused by high fat/Calorie diet plus high fructose and glucose in drinking water 68届美国肝病研究会(AASLD) 年会 美国华盛顿特区
2017: TAP1 Mediated Drug Resistance in Hepatoma Cells through Activation of Hedgehog Signaling 68届美国肝病研究会(AASLD) 年会 美国华盛顿特区
2017: Dicosylhexaenoic Acid Reversed Progression of NASH to Hepatic Fibrosis in Mice by Increasing Ratio ω-3 over ω-6 Fatty Acids.中华医学会消化病分会17届年会 西安
2017: Activation of pluripotent genes in the transformation of NASH and fibrosis to hepatocellular carcinoma 美国肝病研究会主办专题会议: “肝胆道癌症：病理生物学及转化进展” 美国维吉尼亚州
2016: Up-Regulated Hedgehog Signaling in Hepatoma Resistance to Drug Therapy. March 24-25, 2016, Nanjing, China. 第八届（2016）国际生物医药研发创新亚洲峰会及展览2016 The 8th International Biopharmaceutical R&D Innovation New Asia Summit and the Exhibition. 执行主席（Executive Chair）: 肿瘤分子靶向药物革新与精准医学研讨会 (Symposium of Molecular Targeting Cancer therapy Revolution and Precise Medicine).
2016: Progression of Nonalcoholic Steatohepatitis to Hepatic Fibrosis and Microenvironmental Niche for Cancer Development. In the Session of Pathogenesis of Steatohepatitis, fibrosis and carcinogenesis. 第四届上海国际消化系统疾病会议—聚焦脂肪肝与炎症性肠病（The fourth Shanghai International Conference on Digestive Diseases---Focus on Fatty Liver and Inflammatory Bowel Diseases）。 April 22-24, 2016你4月22-24日，上海新华医院. 专场10主持 : Pathogenesis of Alcoholic Liver Diseases.
2016: 非酒精性脂肪性肝炎—肝纤维化和癌症的沃土（Nonalcoholic steatohepatitis—rich soil for hepatic fibrosis and carcinogenesis）。国家自然科学基金委员会医学科学部“肝脏炎症与代谢性疾病的关键科学问题”发展战略研讨会。 主旨发言。2016年2月29-3月日，上海第二军医大学附属长征医院。
2016: Nonalcoholic Steatohepatitis (NASH), Rich Soil for Fibrosis Progression and Cancer Development. International Symposium：Translation from Liver Pathobiology to Clinical Practice, May 13-14, 2016. 大会执行共同主席Executive Chair, 专场主持（Session moderator）。 复旦大学附属中山医院。
2016: 脂肪酸-激发炎症小体活化有助于高脂饲料喂食小鼠肝星状细胞活化. 中华医学会第16次全国消化系病学术会议，2016年9月22-24， 苏州国际博览中心。 会议墙壁交流。
2016: 豪猪信号通路通过ABCC1 转运载体影响肝癌细胞对药物治疗的敏感性。. 中华医学会第16次全国消化系病学术会议，2016年9月22-24， 苏州国际博览中心。 会议墙壁交流。
2016: 吴健： 利用手术切除标本预测肝肿瘤的药物敏感性及转移. 2016 中国上海“东方美谷“精确健康与第三方检验检测高峰论坛。 2016年12月15日。 上海奉贤。
2015： Hedgehog Signaling as a Molecular Target for Aggressiveness and Metastasis of Hepatocellular Carcinoma. 2015 the 7th International Biopharmaceutical R&D Innovation Asia Summit, 2015年1月20-21日，上海普陀上海明捷万丽酒店， 分会场主持。
2015： Aberrant Hedgehog signaling is responsible for the highly metastatic property of HCC subpopulation. China University of Pharmaceutics Jiangning Campus. 2015年6月23日. 江苏南京市.
2015: Aberrant hedgehog signaling is responsible for the highly invasive behavior of a subpopulation of hepatoma cells. Annual Meeting of the American Association for Cancer Research (AACR). April5-9, 2014, San Diego, CA, USA.
2014: Reversal of CLA-Induced Nonalcoholic Fatty Liver Disease (NAFLD) and Insulin Resistance (IR) by DHA in a Mouse Model. the 11th Biennial Congress of International Society for the Study of Fatty acid and lipids (ISSFAL 2014), June 28-July 2, 2014, Stockholm, Sweden.
2014: Invited seminar: Embryonic Stem Cells (ESCs), Induced Pluripotent Stem Cells (iPSCs) and Liver Regenerative Engineering. April 1, 2014， 上海中科院上海分院生物化学细胞生物学研究所.
2014: Hedgehog signaling as a target for improving outcome of refractory HCC therapy. Oct. 8, 2014 ，上海华东师范大学生命科学学院
2014: 英文科研论文撰写技巧及策策略（How to write a successful SCI original article）? 5th Youth Science and Technology Forum, Sept. 26, 2014 ，司法部司法鉴定科学技术研究所。
2014: Hedgehog signaling in HCC metastasis. Session chair and speaker. 12th Annual Congress of International Drug Discovery & Technology 2014, Nov. 17-19, 2014, 江苏苏州市同里.
2014: Leaky Gut and Immune Reconstitution in HIV Patients with Anti-retroviral Therapy. Fudan University-Melbourne University Infection and Immunology Workshop, Nov. 20-21, 2014, 复旦大学上海医学院.
2014: Critical role of hedgehog signaling in the progressiveness of hepatocellular carcinoma) Key Laboratory monthly seminar, Dec. 17, 2014, 复旦大学上海医学院.
2013: Hepatic Stellate cells, the Target for the treatment of Liver Fibrosis. Key Laboratory for the Molecular Medical Virology Laboratory of Ministry of Public Health and Education, March 15, 2013, 复旦大学上海医学院
2013: Identification of Critical miRNAs Modulating Liver Injury, Fibrosis and Growth. 4th International Symposium of RNAi Research and Therapeutics, San Francisco, CA. June 20-12, 2013. Hotel Kabuki, 1625 Post Street, San Francisco, CA 94115, USA.
2013: Non-viral gene therapy from bench to bedside—Identify specific clinical applications for potential polylipid nanoparticles. Biomics Biotechnologies Co., Ltd, E&T Development Area, August 26, 2013， 江苏省南通市.
2013: Molecular Targets for the Treatment of Poorly-Differentiated Hepatoma. Symposium of Cancer stem cells, Targeting Cancer Cell Metabolism. Nov. 15, 2013. 海南省海口市
2013: Polylipid Nanoparticle: Effective non-viral gene transfer agent for preclinical evaluation. Chinese Forum of Biomedical Nanotechnology and pharmacotherapeutics. Nov. 30, 2013, Shanghai, China. The 2nd Prize for the Scientific Technology Achievement Award by the 2013 Annual Meeting of the Professional Committee of Biomedical Nanotechnology. Nov. 2013, 上海
2013: Hepatic stellate cells, the target for the treatment of hepatic fibrosis. Research Symposium of Major Organ Fibrosis organized by Natural Science Foundation of China (NSFC), Dec.. 13-14, 2013. 北京.
2012: Liver Cancer Stem Cells: What we know, and what we do not know about them? Grand Round of Gastroenterology & Hepatology, , March 6th, 2012, UC Davis Medical Center, Sacramento, CA, USA.
2012: Hedgehog signaling and EMT in poorly-differentiated hepatoma subpopulations. May 22, 2012. GI Innovative Tumor Group, Comprehensive Cancer Center, UC Davis Medical Center, Sacramento, CA 95817, USA.
2012: Inhibiting Hedgehog Signaling Suppressed Tumorigenicity, Proliferation and Metastasis in Hepatoma subpopulations. UC Davis Institute for Regenerative Medicine 2012 Retreat. June 20, 2012, Education Building, UC Davis Medical Center, Sacramento, CA 95817, USA.
2012: Hepatology from basics to bedside: Graduate course for postgraduate students in. 10 lectures were delivered on Nov. 23-26, 2012, 南京市东南大学医学院
2012: Hedgehog Signaling in Hepatoma subpopulations. Dec. 3rd. 2012. 重庆市第三军医大学新桥医院
2012: How to write high quality of scientific Papers? Dec. 3rd. 2012.重庆市第三军医大学新桥医院
2012: Develop transplantable liver from recellularized matrix. Nov. 28, 2012. 上海中医药大学附属新华医院肝病研究所.
2012: Polylipid Nanoparticle, a non-viral lipid-based vector for liver gene transfer. Dec. 6. 2012. 复旦大学药学院
主办的国际会议：
2017 The 26th Annual Meeting of the Asian Pacific Association for the Study of Liver Diseases (APASL). Feb. 15-19, 2017, Shanghai, China. Faculty of Organizing committee, and Concurrent Session Chair 03: Inflammation, microenvironment and cancer development. Oral presentation session moderator
2017 The first International Symposium of Infectiology and Applications. Program coordinator and Secretariat General. Nov. 3-4, 2017, Shanghai, China.
2016 The 8th International Biopharmaceutical R&D Innovation New Asia Summit and the Exhibition. Executive Chair, Symposium of Molecular Targeting Cancer Therapy Revolution and Precise Medicine. March 24-25, 2016, Nanjing, China.
2016 The fourth Shanghai International Conference on Digestive Diseases---Focus on Fatty Liver and Inflammatory Bowel Diseases. April 22-24, 2016. Xinhua Hospital, Shanghai, China. Session 10 Moderator: Pathogenesis of Alcoholic Liver Diseases.
2016 International Symposium: Translation from Liver Pathobiology to Clinical Practice, May 13-14, 2016. Executive Chairman, Session moderator. Conference program coordinator. Fudan University-Affiliated Zhongshan Hospital, Shanghai, China.
2015 The 7th International Biopharmaceutical R&D Innovation Asia Summit, Jan. 20-21, 2015, Shanghai, China. Invited speaker and Session Chair (Renaissance Shanghai Putou Hotel, Jan, 20-21, 2015.
2014 Fudan University-Melbourne University Joint Workshop of Infection and Immunology, Fudan University Shanghai Medical College, Shanghai, China. Nov. 20-21, 2014. Program Coordinator and abstract book editor.
2013 Advisory committee of 4th International Symposium of RNAi Research and Therapeutics, June 20-21, 2013, San Francisco, CA.
发表论文
1.Di Ding, Lin-Lin Chen, Ying-Zhen Zhai, Chen-Jian Hou, Li-Li Tao, Qi Chen, Shu-Han Lu, Jian Wu*, Xiu-Ping Liu*. Trichostatin A inhibits the activation of hepatic stellate cells by increasing C/EBP-α acetylation in vivo and in vitro. Sci Rep 2018; 8:4395. DOI: 10.1038/s41598-018-22662-6.
2.Dong-Lei Wang, Wen-Ying Dai, Wen Wang, Ying Wen, Ying Zhou, Yi-Tong Zhao, Jian Wu*, Pei Liu*. Interfering RNA against PKC-α Inhibits TNF-α-induced IP3R1 Expression and Improves Glomerular Filtration Rate in Rats with Fulminant Hepatic Failure. Am J Physiol Renal Physiol 2018: Accepted for publication Jan. 10, 2018. DOI: 10.1152/ajprenal.00433.2016. PMID: **.
3.Gang Xu, Juan Ye, Xue-Jing Liu, Ning-Ping Zhang, Yi-Ming Zhao, Jia Fan, Xiu-Ping Liu, Jian Wu*. Activation of Pluripotent Genes in the Transition of Nonalcoholic Steatohepatitis to Pre-Malignant Lesions. Lab Invest 2017; 97(10):1201–1217, Cover Image.
4.Su Qu, Liang Yan, Bo Fang, Shoudong Ye, Ping Li, Jian Wu*, Di Qu*, Houyan Song*. Generation of Enhanced Definitive Endoderm from Human Embryonic Stem Cells under an Albumin/insulin-free and Chemically Defined Condition. Life Science 2017; 175: 37–46. DOI: 10.1016/j.lfs.2017.03.017. Co-corresponding author
5.Na-Na Duan, Xue-Jing Liu, Jian Wu*. Palmitic Acid Elicits Hepatic Stellate Cells Activation through Inflammasomes and Hedgehog Signaling. Life Science 2017; 176: 42–53. DOI: 10.1016/j.lfs.2017.03.012.
6.Jia Ding, Xiao-Tian Zhou, Hao-Yu Zou, Jian Wu*. Hedgehog Signaling Pathway Affects the Sensitivity of Hepatoma Cells to Drug Therapy through ABCC1 Transporter. Laboratory Investigation 2017; 97(7); 819-832. Published online April 17, 2017. DOI:10.1038/labinvest.2017.34. Corresponding author.
7.Juan Ye, Tian-Sheng Li, Gang Xu, Yi-Ming Zhao, Ning-Ping Zhang, Jia Fan*, Jian Wu*. JCAD Promotes Progression of Non-alcoholic Steatohepatitis to Liver Cancer by Inhibiting LATS2 Kinase Activity. Cancer Research 2017; 77(19): 5287–5300. Cover image.
8.Zhu H-R, Wu J*, Shen X-Z*. Genome-wide association study: new genetic insights into HBV/HCV-related hepatocellular carcinoma genomes. Scand J Gastroenterol 2016；52（2）：209–215. 10.1080/**.2016.**..
9.Feng Li, Huihui Yan, Jiyao Wang*, Cong Li, Jian Wu, Shengdi Wu, Shengxiang Rao, Xihui Gao, Qu Jin. Non-invasively Differentiating Extent of Liver Fibrosis by Visualizing Hepatic Integrin αvβ3 Expression with an MRI Modality in Mice. Biomaterials 2016; 102: 162-174. DOI: 10.1016/j.biomaterials.2016.06.026.
10.Wu J. Utilization of Animal Models to Investigate Nonalcoholic Steatohepatitis-Associated Hepatocellular Carcinoma. Oncotarget 2016; 7(27):42762-42776DOI: 10.18632/oncotarget.8641.
11.Klionsky DJ, Wu J, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 2016 Jan 2;12(1):1-222. PMID: **. DOI: 10.1080/**.2015.**. More than 900 citations.
12.Adkins Y, Fedor DM, Mackey BE, Wu J*, Kelley DS*. Dietary decosahexaenoic acid reverses nonalcoholic steatohepatitis and fibrosis caused by conjugated linoleic acid supplementation in mice. Journal of Functional Foods 2016; 20 (1): 443–452. Online published Dec. 1, 2015. DOI: 10.1016/j.jff.2015.11.028.
13.Asmuth DM, Pinchuk IV, Wu J, Vargas G, Chen X-L, Mann S, Albanese A, Ma Z-M, Saroufeem R, Melcher GP, Cancio PT, Torok NJ, Miller CJ, Powell DW. Role of Intestinal Myofibroblasts in HIV-Associated Intestinal Collagen Deposition and Immune Reconstitution following Combination Antiretroviral Therapy. AIDS 2015;29(8):877-888 DOI: 10.1097/QAD.0636 (impact factor: 6.557). PMID: **.
14.Chang A, Nolta JA, Wu J. Involvement of Mesenchymal Stem Cells in Cancer Progression and Metastases. Current Cancer Drug Targets 2015; 15(2): 88-98. (Corresponding author). Impact factor: 3.582 (5-year average: 5.15). PMID: **.DOI: 10.2174/**66**1
15.Fan Y-H, Ding J, Nguyen S, Liu X-J, Xu G, H Zhou H-Y, Duan N-N, Yang S-M, Zern MA, Wu J*. Aberrant Hedgehog Signaling is Responsible for the Highly Invasive Behavior of a Subpopulation of Hepatoma Cells. Oncogene 2016；35 (1) 116–124, online published. DOI: 10.1038/onc.2015.67, PMID: **.
16.Wecksler AT, Hwang SH, Liu JJ, Inoue H, Morisseau C, Fu SH, Wu J, Weiss RH Hammoc BD. Biological Evaluation of a Novel Sorafenib Analogue, t-CUPM. Cancer Chemother Pharmacol 2015; 22(5):393-396. DOI 10.1007/s00280-014-2626-2, PMID: **.
17.Ding J, Wu J*. Epigenetic Regulation of Hepatic Tumor-Initiating Cells. Frontiers in Bioscience 2015; 20: 946-963 (landmarks). PMID: **; DOI No:10.2741/2842. (Corresponding author).
18.SHIN H-S, SARIN R., DIXIT N, CHAO CC, WU J, IVASHKIV LB, BOWMAN EP, ADAMOPOULOS IE*. Crosstalk among interleukin 23 and DNAX activating protein 12-dependent pathways promotes osteoclastogenesis. J Immunol 2015;194(1):316-24.. DOI: 10.4049/jimmunol.**. PMID: **.
19.Tang W-Q, Xue R-Y, Weng W-X, Wu J, Fang F, Wang Y, Ji L-L, Hu T-T, Liu T-T, Huang X-W, Chen S, Shen X-Z, Zhang S*, Dong L*. BIRC6 promotes hepatocellular carcinogenesis: interaction of BIRC6 with p53 facilitating p53 degradation. Int J Cancer 2015;136(6):E475-87; DOI: 10.1002/ijc.29194. PMID: **.
20.Liu X-J; Xue R-Y; Ji L-L; Zhang X-W; Wu J; Gu J-X; Zhou M-L, Chen S*. Activation of farnesoid X receptor (FXR) protects against fructose-induced liver steatosis via inflammatory inhibition and ADRP reduction. Biochem Biophys Res Commun 2014; 450: 117-123. doi: 10.1016/j.bbrc.2014.05.072.
21.Wang JP, Wang D-L, Wang H-T, Wang Z-H, Wen Y, Sun C-H, Zhao Y-T, Wu J*, Liu P*. Tumor Necrosis Factor-Alpha-Induced Reduction of Glomerular Filtration Rate in Rats with Fulminant Hepatic Failure. Lab Invest 2014; 94: 740–751. DOI:10.1038/labinvest.2014.71.
22.Adkins Y, Schie IW, Fedor D, Reddy A, Nguyen S, Zhou P, Darshan S. Kelley DS*, Wu J*. A novel mouse model of nonalcoholic steatohepatitis with significant insulin resistance. Lab Invest 2013; 93:1313–1322 (corresponding author). DOI: 10.1038/labinvest.2013.123. One image on the cover page.
23.Schie IW, Nolte L, Pedersen TL, Smith Z, Wu J, Yahiatene I, Newman JW, Huser T. Direct Comparison of Fatty Acid Ratios in Single Cellular Lipid Droplets as determined by Comparative Raman Spectroscopy and Gas Chromatography. Analyst 2013;138(21): 6662-6670.
24.Magner NL, Jung Y, Wu J, Nolta JA, Zern MA, Zhou P. Insulin and IGFs Enhance Hepatocyte Differentiation from Human Embryonic Stem Cells via the PI3K/AKT Pathway. Stem Cells 2013; 31:2095-2103. doi: 10.1002/stem.1478.
25.Chang A, Nolta JA, Wu J. Mesenchymal Stem Cells as a Carrier for Targeting Anti-Tumor Therapeutics. In Gerhard Gross & Thomas Haeupl Eds: STEM CELL-DEPENDENT-THERAPIES - MESENCHYMAL STEM CELLS IN CHRONIC INFLAMMATORY DISORDERS. ISBN 978-3-11-024042-9 De Gruyter Publisher, Berlin, Germany. 2013: 353-380 (Senior author).
26.Wu J. Coumarin, an alternative candidate for the treatment of non-alcoholic steatohepatitis? An Invited Commentary in Br J Nutr 2013; 109(9):1542-3. doi:10.1017/S00071**.
27.Fan YH, Wu J. Polylipid nanoparticle, a Novel Lipid-based Vector for Liver Gene Transfer. In Dr. Francisco Martin Edits: Gene Therapy Tools and Potential Applications (ISBN 980-953-307-690-9), Intechopen, Rijeka, Croatia. 2013: 91-107 (Senior author). http://dx.doi.org/10.5772/54270.
28.Wu L-J, Pan Y-D, Pei X-Y, Chen H, Nguyen S, Kashyap A, Liu J, Wu J*. Capturing circulation tumor cells from hepatocellular carcinoma. Cancer Letters 2012; 326: 17-72.
29.Cui Y-Y, Qian J-M, Yao A-H, Ma Z-Y, Qian X-F, Zha X-M, Zhao Y, Ding Q, Liu X-A, Zhao J, Wang S, Wu J*. SOD Mimetic Improves the Function, Growth and Survival of Small Size Graft Liver Transplantation in Rats. Transplantation 2012; 94(7):687–694.
30.Li F, Song Z-J, Li QH, Wu J, Wang J-Y, Xie C, Tu CT, Wang J, Huang X-W, Lu W-Y. Molecular Imaging of Hepatic Stellate Cell Activity by Visualization of Hepatic Integrin βvα3 Expression with SPECT in Rat. Hepatology 2011; 54: 1020-1030.
31.Ellis CL, Ma ZM, Mann SK, Li CS, Wu J, Knight TH, Yotter Y, Hayes TL, Maniar AH, Troia-Cancio PV, Overman HA, Torok NJ, Albanese A, Rutledge JC, Shacklett BL, Miller CJ, Pollard RB, Asmuth DM. Phylogenetic order-level of stool microbiota in HIV-infected subjects. J AIDS 2011; 57:363-370.
32.Ghaedi M, Tuleuova N, Zern MA, Wu J, Revzin A. Bottom-Up Stimulation and Hepatic Differentiation of Mesenchymal Stem Cells Cultured on HGF-Containing Surfaces. Biochem Biophys Res Commun 2011; 407:295-300.
33.Ghaedi M, Soleimani M, Sheikhfatollahi M, Azadmanesh K, Lotfi AS, Wu J*. Mesenchymal stem cells as vehicles for targeted delivery of antiangiogenic protein to solid tumor. J Gene Med 2011：13: 171-180.
34.Chen XL, Lingala S, Zern MA, Nolta JA, Wu J*. Epithelial Mesenchymal Transition and Hedgehog Signaling Activation are Associated with Chemoresistance and Enhanced Metastasis of Poorly-Differentiated Hepatoma Cells. J Hepatol 2011; 55: 838-845 (136 citations by March 2018)
35.Zhou P, Lessa N, Estrada DC, Lingala S, Zern MA, Nolta JA, Wu J*. Decellularized Liver Matrix as a Carrier for Transplantation of Human Fetal and Primary Hepatocytes in Mice. Liver Transplant 2011: 17:418-427.
36.Chen XL, Murad M, Cui Y-Y, Yao L-J, Venugopal SK, Dawson K, Wu J*. miRNA Signatures in Remaining Liver of 50% Partial Hepatectomy and Small Size Liver Graft in Rat Recipients. Transplantation; 2011: 91:293-299.
37.Schie IW, Wu J, Rutledge JC, Zern MA, Huser T*. Label-free monitoring of lipid droplet formation in living primary hepatocytes after treatment with lipoprotein lipolysis products. J Biophotonics 2011; 4(6):425-34.
38.Lingala S, Cui Y-Y, Chen X, Ruebner BH, Qian X-F, Zern MA, Wu J*. Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma. Exp Mol Pathol 2010; 89:27-35 (PMID: **). The most downloaded paper in the journal, and an image on the face page.
39.Yoon S-J, Kim T-H, Natarajan A, Wang S-S, Choi MS, Wu J*, Zern MA, Senthil K Venugopal. Acute liver injury up-regulates microRNA-491_5p in mice, and its over-expression sensitizes Hep G2 cells for TNF-α-induced apoptosis. Liver Int 2010; 30: 276-287.
40.Venugopal SK, Jiang J, Kim T-H, Li Y, Wang S-S, Torok NJ, Wu J, Zern MA*. Liver fibrosis causes down-regulation of miRNA-150 and miRNA-194 in hepatic stellate cells and their over-expression causes decreased stellate cell activation. Am J Physiol 2010; 298: G101-G106.
41.Tatsukawa H, Fukaya Y, Frampton F, Martinez-Fuentes A, Suzuki K, Kuo K-F, Nagatsuma K, Shimokado K, Okuno M, Wu J, Iismaa S, Matsuura T, Tsukamoto H, Zern MA, Graham R, Kojima S. Role of Transglutaminase 2 in Liver Injury via Crosslinking and Silencing of Transcription Factor, Sp1. Gastroenterology 2009; 136:1783-95 (Impact factor: 12.455).
42.Nyunt T, Dicus CW, Yappert MC, Cui YY, Huser TR, Nantz MH, Wu J*. Physico-Chemical characterization of Poly(Cationic) Lipid and Polylipid Nanoparticles for Liver-Based Gene Delivery. Bioconjugate Chemistry 2009; 20:2047-2054.
43.Wu J*, Hecker JH, Chiamvimonvat N. Antioxidant gene transfer for ischemic diseases. Advanced Drug Delivery Reviews. 2009; 61: 351-363.
44.Kim JW, Wu J*. RNAi, a Powerful Research Tool and Potential Molecular Therapy for Liver Diseases. In Yamada K & Hayashi S Eds: Small Interfering RNA: New Research. ISBN: 978-1-60692-158-6. Nova Science Publishers, Inc. Hauppauge, NY. 2009: 2009: 101-120 (senior author).
45.Ma XC, Duan YY, Catana AM, Jung JJ, Wu J, VandeVoort K, Zern MA*. Differentiation of rhesus monkey embryonic stem cells along hepatocyte lineage. Cloning & Stem Cells 2008; 10:485-94.
46.Liu PG, He SQ, Zhang YH, Wu J*. Protective effects of apocynin and allopurinol on ischemia /reperfusion-induced liver injury in mice. World J Gastroenterol 2008; 14: 2832-2837.
47.Choi MS, Catana AM, Wu J, Borowsky AD, Gambhir SS, Gupta S, Zern MA*. Use of Bioluminescent Imaging to trace the transplantation of immortalized human fetal hepatocytes into mice. Cell Transplant 2008;17: 899-909.
48.Venugopal SK, Wu J, Catana AM, Eisenbud L, He SQ, Duan YY, Bishop C, Follenzi A, Gupta S, Zern MA*. Lentivirus-mediated copper-zinc superoxide dismutase gene delivery protects the liver in mice against oxidative stress. Liver Int 2007; 27: 1311-22.
49.Zhang YH, Venugopal SK, He SQ, Liu PG, Wu J, Zern MA*. The role of novel protein kinase δ and ε isoforms for ethanol-induced apoptosis in primary rat hepatocytes. Cell Signaling 2007; 19:2339-2350.
50.Kim JW, Zhang YH, Zern MA, Rossi JJ, Wu J*. Short Hairpin RNA Causes the Methylation of Transforming Growth Factor-β Receptor II Promoter and Silencing of the Target Gene in Rat Hepatic Stellate Cells. Biochem Biophys Res Commun 2007; 359: 292-297.
51.Qian JM, Zhang H, Wu XF, Chen XP, Wu J*. Improvement of recipient survival after small size graft liver transplantation in rats with pre-ischemic manipulation or administering antisense against NF-κB. Transplant Int 2007; 20: 784-789.
52.Du SL, Pan H, Wang J, Lu WY, Wu J*, Wang JY*. Cyclic RGD Peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats. J Pharmacol Exp Ther 2007; 322: 560-568 (co-senior author).
53.He SQ, Zhang YH, Venugopal SK, Dicus CW, Perez RV, Ramsamooj R, Nantz MH, Zern MA, Wu J. Delivery of antioxidative enzyme genes protects against ischemia/reperfusion-induced liver injury in mice. Liver Transplant 2006; 12: 1869-1879 (senior author).
54.Yamamoto N, Wu J, Catana A, Cai H,Strom S, Novikoff PM, Zern MA*. An optimal culture condition maintains human hepatocyte phenotype after long term culture. Hepatol Res 2006; 35:169-177.
55.Zhang YH, Gu JF, Zhao LL, He LF, Qian WB, Wang JH, Wang YG, Qian QJ, Qian C, Wu J*, Liu XY*, Complete elimination of colorectal tumor xenograft by combined MnSOD and TRAIL gene-virotherapy. Cancer Research 2006; 66(8): 4291-4298 (co-senior author).
56.Prosser CC, Yen RD, Wu J. Molecular therapy for hepatic injury and fibrosis – where are we? (editorial) World J Gastroenterol 2006, 12: 509-515.
57.Zhan S-S, Jiang XS, Wu J, Halsted C, Zern MA, Torok NJ. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and it is associated with liver fibrosis in vivo. Hepatology 2006; 43: 435-443.
58.Yen DR, Zern MA, Wu J*. Molecular therapy for hepatic fibrosis (invited book chapter). In Frank Columbus Edits: Focus on Chemotherapy Research, Nova Science Publishers, Inc. Hauppauge, NY. 2006:1-23.
59.Wu J. Inhibition of hepatitis viral replication by siRNA. Exp Opin Biol Ther 2004; 4(10): 1649-1659.
60.Duan Y-Y, Wu J, Zhu J-L, Liu S-L, Ozaki I, Strayer DS, Zern MA*. Gene therapy for human alpha 1-antitrypsin deficiency in an animal model using sv40-derived vectors. Gastroenterology 2004; 127: 1222-1232.
61.Wu J*, Liu L, Yen YD, Catana CM, Michael H. Nantz, Zern MA. Liposome-mediated extracellular superoxide dismutase gene delivery protects against acute liver injury in mice. Hepatology 2004; 40: 195-204 (senior author). Impact factor: 11.67
62.Wu J, Zern MA*. Tissue transglutaminase, a key enzyme involved in liver diseases. Hepatology Research 2004; 29: 1-8
63.Shirahashi H, Wu J, Yamamoto N, Wege H, Wager B, Okita K, Zern MA*. Differentiation of human and mouse embryonic stem cells along a hepatocyte lineage. Cell Transplant 2004; 13: 197-211.
64.Wege H, Le HT, Chui MS, Liu L, Wu J, Giri R, Malhi H, Sappal BS, Kumaran V, Gupta S, Zern MA. Telomerase reconstitution immortalizes human fetal hepatocytes without disrupting their differentiation potential. Gastroenterology 2003; 124: 432-444. Impact factor: 12.455
65.Liu L, Zern MA, Lizarzburu ME, Nantz MH, Wu J*. Poly(cationic lipid)-mediated in vivo gene delivery to mouse liver. Gene Therapy 2003; 10: 180-187 (senior author).
66.Wu J, Nantz MH, Zern MA*. Targeting hepatocytes for drug and gene delivery---emerging novel approaches and applications. Front Biosci 2002; 7:d717-725 (senior author).
67.Wege H, Wu J, Santos, RM, Zern MA*. Hepatocyte-based therapies for liver diseases: novel strategies and updates. J Port Gastroenterol 2001; 8: 134-142.
68.Wu J, Lizarzaburu ME, Kurth MJ, Liu L, Wege H, Zern MA, Nantz MH. Cationic lipid polymerization as a novel approach for constructing new DNA delivery agents. Bioconjugate Chem 2001; 12: 251-257
69.Wege H, Wu J, Zern MA*. Novel therapeutic modalities for hepatic disease. In: Kiwmu Okita Eds, Frontiers in Hepatology /Liver Cirrhosis. Springer-Verlag Tokyo, Tokyo. 2001:17-29.
70.Di Campli C, Nocente R, Costamagna G, Gentiloni N, Burioni R, Wu J, Armuzz A, Zern MA, Gasbarrini G, Gasbarrini A. No evidence of Helicobacter pylori sequences in pancreatic juices of patients affected by chronic pancreatitis. Int J Pancreatol 2000; 28:181-185.
71.Wu J, Zern MA*. Hepatic stellate cells: a target for the treatment of liver fibrosis. J Gastroenterol 2000; 35: 665-672 (more than 200 citations by 2018).
72.Wu J, Liu SL, Zhu JL, Norton PA, Nojiri S, Hoek JB, Zern MA. Tissue transglutaminase (tTG) functions as a G protein and as a cross-linking molecule in ethanol-induced inhibition of hepatocyte proliferation. J Biol Chem 2000; 275:22213-22219.
73.Wu J, Danielsson Å, Zern MA. Use of isolated hepatocytes in study of xenobiotic hepatotoxicity. In Berry MN & Edwards AM, Eds. Hepatocyte Review, Kluwer Academic Publishers, Dordercht, The Netherlands. 2000: 455-474 (senior author).
74.DiCampli C, Wu J, Zern M.A. Liver targeting approaches for fibrosis. Alcoholism: Clin Exp Res 1999; 23: 950-954.
75.Wu J*, Danielsson Å, Zern MA. Toxicity of hepatotoxins: new insights into mechanisms and therapy. Exp Opin Invest Drugs 1999; 8: 585-607 (senior author).
76.Di Campli C, Wu J, Zern MA. Gene therapy for human liver disease. Eur J Gastroenterol Hepatol 1999; 11: 421-429.
77.Wu J*, Wu GY, Zern MA. The prospects of hepatic drug delivery and gene therapy. Exp Opin Invest Drugs 1998; 7: 1795-1817 (senior author).
78.Zhu JL, Wu J, Frizell E, Liu SL, Bashey R, Rubin R, Norton PA. Zern MA*. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 1999; 117:1198-1204. Impact factor: 12.455
79.Wu J, Liu P, Zhu JL, Maddukuri S, Zern MA. Increased liver up-take of liposomes and improved targeting efficacy by labeling with asialofetuin in rodents. Hepatology 1998; 27: 772-778. Impact factor: 11.67
80.Wu J, Kuncio GS, Zern MA. Human liver growth in fibrosis and cirrhosis. In Strain AJ, Diehl AM, Eds. Liver Growth and Repair. Chapman & Hall, London. 1998: 558-576.
81.Wu J, Karlsson K, Danielsson Å. Effects of vitamin E, ascorbic acid and catalase on bromobenzene- and hydrogen peroxide-induced intracellular oxidation and single strand DNA breakage in Hep G2 cells. J Hepatol 1997; 26: 669-677.
82.Wu J. Zern MA. Modification of liposomes for liver targeting. J Hepatol 1996; 24:757-763.
83.Wu J, Norton PA. Animal models of liver fibrosis. Scand J Gastroenterol 1996; 31:1137-1143.
84.Wu J, Karlsson K, Danielsson Å. Protective effect of Trolox C, vitamin C and catalase on bromobenzene-induced damage to rat hepatocytes. Scand J Gastroenterol 1996; 31: 797-803.
85.Wu J, Söderbergh H, Karlsson K, Danielsson Å. Protective effect of S-adenosyl-L-methionine on bromobenzene- or D-galactosamine toxicity to isolated rat hepatocytes. Hepatology 1996; 23: 359-365. Impact factor: 11.67
86.Wu J, Danielsson Å, Lindström P, Karlsson K, Sehlin J. The protective effects of calcium channel blockers on bromobenzene-induced damage to isolated rat hepatocytes. inhibition of phenylephrine stimulated calcium oscillations. Scand J Gastroenterol 1995; 30: 590-600 (senior author).
87.Jin TY, Nordberg GF, Sehlin J, Leffler P, Wu J, Sehlin J*. Augmented susceptibility of spontaneously diabetic mice to nephrotoxicity induced by cadmium-metallothionein. Toxicology 1994; 89: 81-90.
88.Wu J*, Lindström P, Danielsson Å, Sehlin J. Insulin secretion in pancreatic islets from rats with cirrhosis. J Hepatol 1994; 21: 332-339 (senior author). impact factor: 10.4
89.Jiang Z, You DY, Chen XC and Wu J*. Monitoring of serum markers of fibrosis during CCl4-induced liver damage. Effects of anti-fibrotic agents. J Hepatol 1992; 16:282-289.
学术专著
1.Jian Wu. Pathogenesis of Hepatocellular Damage, Hepatic Fibrosis and Cirrhosis in the Rat. Prevention of Liver Damage and Inhibition of Fibrogenesis. Ph. D. Thesis, University of Umeå, Sweden. New Series No. 418, ISSN 0346-6612, ISBN 91-7174-968-31994. 1994
2.Jian Wu & Pampla A. Norton. Editors: Hepatic Fibrosis and Targeting therapy. Special Issue of Frontiers in Bioscience: 2002
(https://www.bioscience.org/special-issue-details?editor_id=684)
3. Copy Editor: World Journal of Gastroenterology 2007; Vol. 13, Issue 29. 2007
4. Jian Wu. Editor: Cytochrome P450 Enzymes: Biochemistry, Pharmacology, and Health Implications. Nova Science Publishers, Inc. Hauppauge, NY 11788-3619, USA. 2014: 194 pages. ISBN: 978-1-61942-209-4. 2014
申请或授权专利
授权专利
1.Extracellular superoxide dismutase gene delivery to prevent oxidative injury. UCD#2003-483 Internationally covered.
2. Decellularized Liver Matrix for Transplantation of Stem Cells or Hepatocytes. PCT/US2011/068214。
申请专利
1.吴健、丁佳、周笑天。高耐药性Huh-7-DN肝癌细胞株。 专利申请号： 2.8. 立项日期： 2016-07-05.
2.JCAD肝癌的潜在诊断或分子靶点作用。 专利申请号： #.9. 吴健、叶娟、樊嘉 2017-8-15
3.微小流体共培养装置的设计 。专利申请号：#4.8，吴健 2017-8-15
主要发表文章：
1. Jiang Z, You DY, Chen XC and Wu J. Monitoring of serum markers of fibrosis during CCl4-induced liver damage. Effects of anti-fibrotic agents. J Hepatol 1992; 16:282-289 (Corresponding author).
2. Wu J, Lindström P, Danielsson Å, Sehlin J. Insulin secretion in pancreatic islets from rats with cirrhosis. J Hepatol 1994; 21: 332-339 (Corresponding author).
3. Wu J, Söderbergh H, Karlsson K, Danielsson Å. Protective effect of S-adenosyl-L-methionine on bromobenzene- or D-galactosamine toxicity to isolated rat hepatocytes. Hepatology 1996; 23: 359-365.
4. Wu J, Karlsson K, Danielsson Å. Effects of vitamin E, ascorbic acid and catalase on bromobenzene- and hydrogen peroxide-induced intracellular oxidation and single strand DNA breakage in Hep G2 cells. J Hepatol 1997; 26: 669-677.
5. Wu J, Liu P, Zhu JL, Maddukuri S, Zern MA. Increased liver up-take of liposomes and improved targeting efficacy by labeling with asialofetuin in rodents. Hepatology 1998; 27: 772-778.
6. Zhu JL, Wu J, Frizell E, Liu SL, Bashey R, Rubin R, Norton PA. Zern MA. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 1999; 117:1198-1204.
7. Wu J, Liu SL, Zhu JL, Norton PA, Nojiri S, Hoek JB, Zern MA. Tissue transglutaminase (tTG) functions as a G protein and as a cross-linking molecule in ethanol-induced inhibition of hepatocyte proliferation. J Biol Chem 2000; 275:22213-22219.
8. Wu J, Lizarzaburu ME, Kurth MJ, Liu L, Wege H, Zern MA, Nantz MH. Cationic lipid polymerization as a novel approach for constructing new DNA delivery agents. Bioconjugate Chem 2001; 12: 251-257.
9. Liu L, Zern MA, Lizarzburu ME, Nantz MH, Wu J. Poly(cationic lipid)-mediated in vivo gene delivery to mouse liver. Gene Therapy 2003; 10: 180-187 (Corresponding author).
10. Wege H, Le HT, Chui MS, Liu L, Wu J, Giri R, Malhi H, Sappal BS, Kumaran V, Gupta S, Zern MA. Telomerase reconstution immortalizes human fetal hepatocytes without disrupting their differentiation potential. Gastroenterology 2003; 124: 432-444.
11. Shirahashi H, Wu J, Yamamoto N, Wege H, Wager B, Okita K, Zern MA. Differentiation of human and mouse embryonic stem cells along a hepatocyte lineage. Cell Transplant 2004; 13: 197-211.
12. Wu J, Liu L, Yen YD, Catana CM, Michael H. Nantz, Zern MA. Liposome-mediated extracellular superoxide dismutase gene delivery protects against acute liver injury in mice. Hepatology 2004; 40: 195-204 (Corresponding author).
13. Duan Y-Y, Wu J, Zhu J-L, Liu S-L, Ozaki I, Strayer DS, Zern MA. Gene therapy for human alpha 1-antitrypsin deficiency in an animal model using sv40-derived vectors. Gastroenterology 2004; 127: 1222-1232. 31.
14. Zhan S-S, Jiang XS, Wu J, Halsted C, Zern MA, Torok NJ. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and it is associated with liver fibrosis in vivo. Hepatology 2006; 43: 435-443.
15. Zhang YH, Gu JF, Zhao LL, He LF, Qian WB, Wang JH, Wang YG, Qian QJ, Qian C, Wu J, Liu XY, Complete elimination of colorectal tumor xenograft by combined MnSOD and TRAIL gene-virotherapy. Cancer Research 2006; 66(8): 4291-4298 (co-corresponding author).
16. He SQ, Zhang YH, Venugopal SK, Dicus CW, Perez RV, Ramsamooj R, Nantz MH, Zern MA, Wu J. Delivery of antioxidative enzyme genes protects against ischemia/reperfusion-induced liver injury in mice. Liver Transplant 2006; 12: 1869-1879 (Corresponding author).
17. Du SL, Pan H, Wang J, Lu WY, Wu J, Wang JY. Cyclic RGD Peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats. J Pharmacol Exp Ther 2007; 322: 560-568 (co-corresponding author).
18. Kim JW, Zhang YH, Zern MA, Rossi JJ, Wu J. Short hairpin RNA causes the methylation of transforming growth factor-b receptor II promoter and silencing of the target gene in rat hepatic stellate cells. Biochem Biophys Res Commun 2007; 359: 292-297 (corresponding author).
19. Zhang YH, Venugopal SK, He SQ, Liu PG, Wu J, Zern MA. The role of novel protein kinase d and e isoforms for ethanol-induced apoptosis in primary rat hepatocytes. Cell Signaling 2007; 19:2339-2350.
20. Choi MS, Catana AM, Wu J, Borowsky AD, Gambhir SS, Gupta S, Zern MA. Use of Bioluminescent Imaging to trace the transplantation of immortalized human fetal hepatocytes into mice. Cell Transplant 2008;17: 899-909.
21. Ma XC, Duan YY, Catana AM, Jung JJ, Wu J, VandeVoort K, Zern MA. Differentiation of rhesus monkey embryonic stem cells along hepatocyte lineage. Cloning & Stem Cells 2008; 10:485-94.
22. Wu J, Hecker JH, Chiamvimonvat N. Antioxidant gene transfer for ischemic diseases. Adv Drug Delivery Rev 2009; 61: 351-363 (Corresponding author).
23. Nyunt T, Dicus CW, Yappert MC, Cui YY, Huser TR, Nantz MH, Wu J. Physico-chemical characterization of poly(cationic) lipid and polylipid nanoparticles for liver-based gene delivery. Bioconjugate Chem 2009; 20:2047-2054 (Corresponding author).
23. Tatsukawa H, Fukaya Y, Frampton F, Martinez-Fuentes A, Suzuki K, Kuo K-F, Nagatsuma K, Shimokado K, Okuno M, Wu J, Iismaa S, Matsuura T, Tsukamoto H, Zern MA, Graham R, Kojima S. Role of Transglutaminase 2 in Liver Injury via Crosslinking and Silencing of Transcription Factor, Sp1. Gastroenterology 2009; 136:1783-95
25. Venugopal SK, Jiang J, Kim T-H, Li Y, Wang S-S, Torok NJ, Wu J, Zern MA. Liver fibrosis causes down-regulation of miRNA-150 and miRNA-194 in hepatic stellate cells and their over-expression causes decreased stellate cell activation. Am J Physiol 2010; 298: G101-G106.
26. Yoon S-J, Kim T-H, Natarajan A, Wang S-S, Choi MS, Wu J, Zern MA, Senthil K Venugopal. Acute liver injury up-regulates microRNA-491_5p in mice, and its over-expression sensitizes Hep G2 cells for TNF-a-induced apoptosis. Liver Int 2010; 30: 276-287.
27. Lingala S, Cui Y-Y, Chen X, Ruebner BH, Qian X-F, Zern MA, Wu J. Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma. Exp Mol Pathol 2010; 89:27-35 (Corresponding author).
28. Schie IW, Wu J, Rutledge JC, Zern MA, Huser T. Label-free monitoring of lipid droplet formation in living primary hepatocytes after treatment with lipoprotein lipolysis products. J Biophotonics 2011; 4:425-34.
29. Chen XL, Murad M, Cui Y-Y, Yao L-J, Venugopal SK, Dawson K, Wu J. miRNA Signatures in Remaining Liver of 50% Partial Hepatectomy and Small Size Liver Graft in Rat Recipients. Transplantation; 2011: 91:293-299 (Corresponding author).
30. Zhou P, Lessa N, Estrada DC, Lingala S, Zern MA, Nolta JA, Wu J. Decellularized Liver Matrix as a Carrier for Transplantation of Human Fetal and Primary Hepatocytes in Mice. Liver Transplant 2011: 17:418-427 (Corresponding author).
31. Chen XL, Lingala S, Zern MA, Nolta JA, Wu J. Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and enhanced metastasis of poorly-differentiated hepatoma cells. J Hepatol 2011; 55: 838-845 (Corresponding author).
32. Ghaedi M, Soleimani M, Sheikhfatollahi M, Azadmanesh K, Lotfi AS, Wu J. Mesenchymal stem cells as vehicles for targeted delivery of antiangiogenic protein to solid tumor. J Gene Med 2011：13: 171-180 (Corresponding author).
33. Ghaedi M, Tuleuova N, Zern MA, Wu J, Revzin A. Bottom-Up Stimulation and Hepatic Differentiation of Mesenchymal Stem Cells Cultured on HGF-Containing Surfaces. Biochem Biophys Res Commun. 2011; 407:295-300.
34. Ellis CL, Ma ZM, Mann SK, Li CS, Wu J, Knight TH, Yotter Y, Hayes TL, Maniar AH, Troia-Cancio PV, Overman HA, Torok NJ, Albanese A, Rutledge JC, Shacklett BL, Miller CJ, Pollard RB, Asmuth DM. Phylogenetic order-level of stool microbiota in HIV-infected subjects. J AIDS 2011; 57:363-370.
35. Li F, Song Z-J, Li QH, Wu J, Wang J-Y, Xie C, Tu CT, Wang J, Huang X-W, Lu W-Y. Molecular imaging of hepatic stellate cell activity by visualization of hepatic integrin bva3 expression with SPECT in rat. Hepatology 2011; 54: 1020-1030.
36. Cui Y-Y, Qian J-M, Yao A-H, Ma Z-Y, Qian X-F, Zha X-M, Zhao Y, Ding Q, Liu X-A, Zhao J, Wang S, Wu J. SOD Mimetic Improves the Function, Growth and Survival of Small Size Graft Liver Transplantation in Rats. Transplantation 2012; 94:687–694 (Corresponding author).
37. Wu L-J, Pan Y-D, Pei X-Y, Chen H, Nguyen S, Kashyap A, Liu J, Wu J. Capturing circulation tumor cells from hepatocellular carcinoma. Cancer Letters 2012; 326: 17-72 (Corresponding author)
38. Magner NL, Jung Y, Wu J, Nolta JA, Zern MA, Zhou P. Insulin and IGFs enhance hepatocyte differentiation from human embryonic stem cells via the PI3K/AKT pathway. Stem Cells 2013; 31:2095-2103.
39. Schie IW, Nolte L, Pedersen TL, Smith Z, Wu J, Yahiatene I, Newman JW, Huser T. Direct comparison of fatty acid ratios in single cellular lipid droplets as determined by comparative Raman spectroscopy and gas chromatography. Analyst 2013; 138: 6662-6670.
40. Adkins Y, Schie IW, Fedor D, Reddy A, Nguyen S, Zhou P, Darshan S. Kelley DS, Wu J. A novel mouse model of nonalcoholic steatohepatitis with significant insulin resistance. Lab Invest 2013; in press (corresponding author). DOI: 10.1038/labinvest.2013.123.